参考文献/References:
[1]Cottin V,Brown KK.Interstitial lung disease associated with systemic sclerosis (SSc-ILD)[J].Respir Res,2019,20(1):13.[2]Denton CP,Khanna D.Systemic sclerosis[J].Lancet,2017,390(10103):1685-1699.[3]Meyer KC.Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis[J].Expert Rev Respir Med,2017,11(5):343-359.[4]Araújo FC,Camargo CZ,Kayser C.Validation of the ACR/EULAR classification criteria for systemic sclerosis in patients with early scleroderma[J].Rheumatol Int,2017,37(11):1825-1833.[5]Raghu G,Remy-Jardin M,Myers JL,et al.Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline[J].Am J Respir Crit Care Med,2018,198(5):e44-e68.[6]Travis WD,Costabel U,Hansell DM,et al.An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias[J].Am J Respir Crit Care Med,2013,188(6):733-748.[7]American Thoracic Society,European Respiratory Society.American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001[J].Am J Respir Crit Care Med,2002,165(2):277-304.[8]Camiciottoli G,Orlandi I,Bartolucci M,et al.Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life[J].Chest,2007,131(3):672-681.[9]Distler O,Highland KB,Gahlemann M,et al.Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease[J].N Engl J Med,2019,380(26):2518-2528.[10]Swarnakar R,Garje Y,Markandeywar N,et al.Exploring the common pathophysiological links between IPF, SSc-ILD and post-COVID fibrosis[J].Lung India,2022,39(3):279-285.[11]Cheng JZ,Wilcox PG,Glaspole I,et al.Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases[J].Respirology,2017,22(8):1592-1597.[12]Newton DA,Lottes RG,Ryan RM,et al.Dysfunctional lactate metabolism in human alveolar type Ⅱ cells from idiopathic pulmonary fibrosis lung explant tissue[J].Respir Res,2021,22(1):278.[13]Kishaba T,Nei Y,Momose M,et al.Clinical Characteristics Based on the New Criteria of Acute Exacerbation in Patients with Idiopathic Pulmonary Fibrosis[J].Eurasian J Med,2018,50(1):6-10.[14]Okamoto S,Tsuboi H,Noma H,et al.Predictive Factors for Pneumomediastinum During Management of Connective Tissue Disease-related Interstitial Lung Disease: A Retrospective Study[J].Intern Med,2021,60(18):2887-2897.[15]Cao M,Sheng J,Qiu X,et al.Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study[J].BMC Pulm Med,2019,19(1):215.[16]Yoo H,Hino T,Han J,et al.Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management[J].Eur J Radiol Open,2020,8:100311.[17]Wu X,Yin C,Chen X,et al.Idiopathic Pulmonary Fibrosis Mortality Risk Prediction Based on Artificial Intelligence: The CTPF Model[J].Front Pharmacol,2022,13:878764.[18]Luppi F,Kalluri M,Faverio P,et al.Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management[J].Respir Res,2021,22(1):109.[19]Khanna D,Tashkin DP,Denton CP,et al.Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease[J].Am J Respir Crit Care Med,2020,201(6):650-660.[20]Walkoff L,White DB,Chung JH,et al.The Four Corners Sign: A Specific Imaging Feature in Differentiating Systemic Sclerosis-related Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis[J].J Thorac Imaging,2018,33(3):197-203.
相似文献/References:
[1]孙 杰,李 洋.系统性硬化症纤维化治疗新靶点研究[J].医学信息,2018,31(09):56.[doi:10.3969/j.issn.1006-1959.2018.09.018]
SUN Jie,LI Yang.A New Target for the Treatment of Systemic Sclerosis with Fibrosis[J].Journal of Medical Information,2018,31(10):56.[doi:10.3969/j.issn.1006-1959.2018.09.018]
[2]冯彩云.胺碘酮导致间质性肺病患者的1例分析[J].医学信息,2018,31(10):191.[doi:10.3969/j.issn.1006-1959.2018.10.068]
[3]程丽丽,黄传兵,汤忠富,等.从肺论治系统性硬化症合并间质性肺病的经验举隅[J].医学信息,2022,35(10):155.[doi:10.3969/j.issn.1006-1959.2022.10.039]
[4]王海燕,唐小葵.系统性硬化症相关间质性肺病的治疗[J].医学信息,2018,31(19):60.[doi:10.3969/j.issn.1006-1959.2018.19.020]
WANG Hai-yan,TANG Xiao-kui.Treatment of Systemic Sclerosis-related Interstitial Lung Disease[J].Journal of Medical Information,2018,31(10):60.[doi:10.3969/j.issn.1006-1959.2018.19.020]
[5]孟琳非,黄伟健,酆孟洁,等.基于聚类分析对慢性肺部疾病表型的研究进展[J].医学信息,2019,32(07):44.[doi:10.3969/j.issn.1006-1959.2019.07.015]
MENG Lin-fei,HUANG Wei-jian,FENG Meng-jie,et al.Advances in Research on Phenotypes of Chronic Lung Diseases Based on Cluster Analysis[J].Journal of Medical Information,2019,32(10):44.[doi:10.3969/j.issn.1006-1959.2019.07.015]
[6]李 莘,吴 琦.经支气管冷冻肺活检在间质性肺疾病病理诊断中的应用[J].医学信息,2020,33(21):32.[doi:10.3969/j.issn.1006-1959.2020.21.010]
LI Xin,WU Qi.Application of Transbronchial Frozen Lung Biopsy in Pathological Diagnosis of Interstitial Lung Disease[J].Journal of Medical Information,2020,33(10):32.[doi:10.3969/j.issn.1006-1959.2020.21.010]
[7]刘孟国,傅雯雯.警报素在系统性硬化症发病机制中的作用[J].医学信息,2021,34(04):40.[doi:10.3969/j.issn.1006-1959.2021.04.011]
LIU Meng-guo,FU Wen-wen.The Role of Alarmins in the Pathogenesis of Systemic Sclerosis[J].Journal of Medical Information,2021,34(10):40.[doi:10.3969/j.issn.1006-1959.2021.04.011]